New Drug Combo Highly Effective Against HIV, HCV Coinfection
A combination of the protease inhibitor grazoprevir and the NS5A inhibitor elbasvir lead to a sustained virologic response (SVR) rate of 96.3% in patients with HIV and hepatitis C virus coinfection, according to a recent investigational study.
In their study, researchers examined data from 218 patients with HIV and hepatitis C coinfection who received a combination of 100 mg of grazoprevir and 50 mg of elbasvir within a single tablet, once daily, for 12 weeks.
__________________________________________________________________________________________________________________________________________________________________
RELATED CONTENT
New Antiviral Drug Regimen Highly Effective Against Hep C
Study Suggests Rates of Hep C Infection Are Underestimated
__________________________________________________________________________________________________________________________________________________________________
Twelve weeks after cessation of treatment, the SVR was 96.3%, with a 100% SVR in participants with cirrhosis.
Researchers noted that SVR rates were slightly lower in patients whose antiviral regimen contained abacavir or rilpivirine, but remained high in those whose antiviral regimen included tenofovir or raltegravir.
The results of the study were presented at the 8th International AIDS Society Conference in Vancouver, British Columbia.
—Michael Potts
Reference:
Rockstroh JK, Nelson M, Katlama C, et al. High efficacy of grazoprevir/elbasvir in HCV genotype 1, 4, and 6-infected patients with HIV co-infection: the phase 3 C-EDGE co-infection study. Paper presented at: 8th International AIDS Society (IAS) Conference. July 21, 2015.